甲地孕酮联合化疗治疗晚期大肠癌疗效观察

目的观察甲地孕酮对晚期大肠癌的辅助治疗作用。方法80例大肠癌通过双盲法,分为试验组40例(化疗 甲地孕酮)和对照组40例(化疗 安慰剂)。结果与对照组相比,试验组患者的近期有效率、TTP、中位生存期和1年生存率分别为55.0%、10个月、23个月和95.0%,均明显高于对照组20.0%、5.9个月、13个月和50.0%,且差异有显著性(P<0.05);毒副作用也较对照组轻。结论甲地孕酮辅助化疗对大肠癌患者具有一定的增效减毒作用。

Clinical observation on treating advanced colorectal cancer with medroxyprogesterone combined with chemotherapy

Objective To study the efficacy of medroxyprogesterone in adjuvant treatment of(MA) patients with advanced colorectal cancer.Methods Eighty patients with pathologically confirmed colorectal cancer were divided double-blindly into MA plus chemotherapy group(MA group) and placebo plus chemotherapy group(placebo group).Results The response rate,time to progress(TTP),median survival time(MST) and 1-year survival rate in MA group were 55.0%,10 months,23 months and 95.0%,and those in placebo group were 20.0%,5.9 months,13 months and 50.0%,respectively.There was obvious statistical difference between the two groups(P<0.05).The adverse reaction of chemotherapy in MA group decreased compared with placebo group.Conclusion The results show that MA combined with chemotherapy can enhance the therapeutic efficacy and reduce the side effect of chemotherapy.